Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

A model way to regulate new drugs that stands up to industry scrutiny

Article Abstract:

The European Agency for the Evaluation of Medicinal Products (Emea) has gained growing respect since it began operating in early 1995. The agency, which is based on London, England, is widely regarded as being efficient, and some observers are even hailing it as the European version of the US Food and Drug Administration. It employs only 113 people directly, but uses the expertise of 2,000 people from universities, research laboratories and hospitals from across Europe.

Author: Grimond, Magnus
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1997
Product development, European Agency for the Evaluation of Medicinal Products

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Limbering up for drugs bid battle

Article Abstract:

Pharmaceutical concern Fisons is finding it very hard to fight off a 1.7 billion pounds sterling hostile takeover bid from competitor Rhone-Poulenc Rorer. Stuart Wallis, chief executive of Fisons, has emphasised his commitment to take very strong action to prevent the takeover going ahead, and believes that the company will be able to remain independent. It will particularly focus on the potential of its new inhalant devices for anti-asthma drugs.

Author: Grimond, Magnus
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1995
Officials and employees, Interview, Wallis, Stuart

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Rhone-Poulenc makes 1.7bn pounds sterling hostile bid for Fisons

Article Abstract:

UK pharmaceuticals concern Fisons is the subject of a 1.7 billion pounds sterling hostile takeover bid from Rhone-Poulenc Rorer. It had been rumoured for some time that Fisons may receive a bid. The offer, worth 240p a share, was rejected immediately, with Fisons claiming that it severely undervalues the group.

Author: Grimond, Magnus
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1995
Planning, Rhone-Poulenc Rorer Inc., RPR

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Pharmaceutical industry, Fisons PLC
Similar abstracts:
  • Abstracts: MI6 supplied parts to Argentine navy. Peace deal sends village fleeing for safety. English lessons open doors to Nato
  • Abstracts: Che-mania revives the ghosts of Castro's revolutionary past. Junta's opponents thrown live into sea
  • Abstracts: The real wreckers of the Union. The paedophile that haunts our imagination. Vive la republique! Et vive le roi!
  • Abstracts: An easy way to make the grade? Sir thought he was witty. Word blind
  • Abstracts: Stick 'em together, pull 'em apart. It's the Velcro age. Sultan Mehmet II and the EU. A world apart from A-levels
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.